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Abstract
OBJECTIVES: The aim of this study is to evaluate the ease of use and the advantages of Sorin Pericarbon Freedom (SPF) stentless valve in
cases of acute bacterial endocarditis and to check the intermediate-term results after the implant of SPF with respect to resistance to infec-
tion, valve deterioration and durability.
METHODS: Between June 2003 and February 2015, 26 patients with active aortic valve bacterial endocarditis underwent aortic valve re-
placement with SPF pericardial stentless aortic prosthesis. The mean age was 57 ± 18 years; 73% of the patients were in preoperative NYHA
class III and VI. Mean Logistic EuroSCORE was 14.2 ± 12.7. Endocarditis occurred in 18 patients with native valves, and in 9 patients with
prosthetic valves (4 mechanical aortic valve prostheses; 5 aortic bioprostheses). Aortic root abscesses were observed in 16 cases (61.5%).
Surgery was emergent in 3 cases (11.5%). Redo surgery was performed in 9 cases (35%). Cumulative follow-up was 126.8 patient-years
(mean 4.9 ± 3.3 years).
RESULTS: Operative hospital mortality was 0% for all patients. Residual mean prosthetic gradient at discharge was 9.4 ± 3.6 mmHg. Neither
residual aortic incompetence nor residual abscess cavity was observed at discharge. Mean ejection fraction at discharge was 54 ± 8% (Min;
Max: 35%; 65%). A total of 4 patients died at follow-up, all for non-cardiac causes. One patient was lost to follow-up. Two patients (8%)
underwent non-valve-related reoperation with 0% mortality. Residual mean gradient at follow-up was 7.2 ± 2.1 mmHg. Three patients
(17%) presented with mild/moderate aortic incompetence and 89% of patients were in NYHA Class I–II at follow-up. At 9 years, actuarial
freedom from valve-related reoperation and from structural valve deterioration was 100%.
CONCLUSIONS: The SPF aortic prosthesis is a true pericardial stentless prosthesis suitable for the treatment of acute bacterial endocarditis.
Intermediate-time results in terms of freedom from reoperation, structural valve deterioration and resistance to infections are satisfactory.
Haemodynamic performances are excellent since a complete exclusion of aortic root abscesses is achieved without any reduction of the
aortic annular diameter, usually due to marsupialization or patch closure of the infected cavities.
Keywords: Aortic valve replacement • Stentless aortic valve prosthesis • Acute bacterial endocarditis
INTRODUCTION
Acute bacterial endocarditis (ABE) of the aortic valve represents a
life-threatening event which is often challenging for the cardiovas-
cular surgeon. Valve replacement remains the most common ap-
proach to this serious disease. Unfortunately, in many cases, an
aortic root abscess is associated with the aortic valve pathology,
making necessary the reconstruction of the left ventricular
outflow tract and the exclusion of the abscess cavity, besides the
aortic valve replacement [1, 2].
An unresolved dispute concerning the prosthesis of choice for
replacing an infected aortic valve alone or associated with a root
abscess is ongoing. We report our 12-year experience of aortic
valve replacement and aortic root reconstruction with the Sorin
Pericarbon Freedom (SPF) stentless pericardial prosthesis in 26
patients with acute endocarditis of the aortic valve, alone or in as-
sociation with aortic root abscesses (61% of cases).
Valve design
The SPF is a true stentless bioprosthesis made of two layers of
bovine pericardium without any fabric reinforcement. The valve,
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which is treated with glutaraldehyde, is detoxified with homocys-
teic acid and stored in an aldehyde-free solution, with no need for
rinsing before implantation [2].
METHODS
Patients
From June 2003 to February 2015, 26 patients underwent aortic
valve replacement (AVR) for active aortic valve endocarditis with an
SPF stentless prosthesis at our institution. In 61.5% of cases, a perian-
nular aortic root abscess was associated with the valve pathology.
There were 22 males (85%) and 4 females (15%), with a mean age of
57 ± 18 years (range: 15–82 years). In 12 patients (46%), the infection
was mainly caused by Staphylococcus spp., by Streptococcus spp. in 8
cases (31%), by Enterococcus spp. in 8 cases (31%) and by
Micrococcus spp. in 1 case (4%). In 15% of infections, more than one
bacterial species was involved. Mean Logistic EuroSCORE was
14.2 ± 12.7; 73% of the patients were in NYHA class III or IV. Three
patients (11%) were operated on an emergency base, according to
the criteria reported in the current guidelines. Seven patients (27%)
underwent concomitant procedures: mitral valve repair (4 patients),
coronary artery bypass (2) and resection of subaortic stenosis (1).
Indications for surgery were intractable sepsis, peripheral emboli and
congestive heart failure. Preoperative characteristics of 26 patients
with ABE are listed in Table 1.
Surgical technique
A standard full sternotomy incision was used in all cases, with
moderately hypothermic extracorporeal circulation, cold crystal-
loid cardioplegia and topical cooling. Associated procedures such
as coronary distal anastomoses or mitral valve surgery were
carried out before aortic valve replacement. SPF is, in our opinion,
an ideal valve substitute in case of bacterial endocarditis, allowing
for left ventricular outflow reconstruction and abscess exclusion
using the pericardial skirt in the inflow side of the prosthesis.
Before implantation, a customized trimming of the inferior skirt
and prosthetic sinuses of pericardial tissue is performed, accord-
ing to the observed patient’s aortic root anatomy and location of
the abscess cavities. The valve was approached through a trans-
verse aortotomy, 1.5–2 cm above the sinotubular junction. After
excision of the native leaflets or of the infected prosthesis, accurate
and complete annular tissue debridement was achieved. The
Table 1: Pre-, intra- and postoperative characteristics of 26 patients with acute bacterial endocarditis
Pre-/intraoperative Discharge Last follow-up
Mean age ± SD [range] 57 ± 18 [15–82]
NYHA
I 1 – 9
II 6 – 9
III 16 – 1
IV 3 – 0
Missing 0 – –
Mean Logistic EuroSCORE ± SD [range] 14.2 ± 12.7 [2.3–51.7]











Mitral valve repair 4
Coronary artery bypass 2
Resection of subaortic stenosis 1
Mean ECC time (h) ± SD [range] 139 ± 27 [94–102]
Mean ACC time (h) ± SD [range] 106.5 ± 24 [63–151]







Mean PPG (mmHg) ± SD [range] 16.2 ± 5.6 [10–35] 16.6 ± 5.5 [11–30]




NYHA: New York Heart Association; EF: ejection fraction; ECC: extracorporeal circulation; ACC: aortic cross-clamp; SD: standard deviation; PPG: pressure peak
gradient; MPG: mean peak gradient.
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abscess cavities, where present, were accurately debrided and cur-
etted. Local disinfection was routinely carried out to remove the
bacteria and the infected tissue. Sizing of the prosthesis is a crucial
part of this procedure. Usually, the choice of the prosthesis is
based on the size of the sinotubular junction rather than on the
aortic annulus, particularly in cases of slightly dilated aortic root.
In cases of bicuspid aortic valves, a tricuspid valve geometry was
restored, paying attention to maintain a correct annular plane.
Exclusion of aortic root abscesses was carried out in 16 patients
(61%). In two cases of extensive damage of the aortic annulus
extended to the aortic sinuses or to the mitro-aortic fibrous con-
tinuity, a patch of bovine pericardium was used in addition to
valve replacement. In all cases, the prosthesis was completely
inverted into the aortic root, and the inflow suture was carried out
first using three 4-0 polypropylene stitches starting at the nadir of
the removed aortic leaflets. Subsequently, the valve was everted
and sutured to the aortic wall in a subcoronary position using
three more continuous 4-0 polypropylene stitches (Fig. 1). The
mean size of the implanted prostheses was 25.6 mm (in 70% of
the cases bigger than size 23), the mean aortic cross-clamp time
(ACC) was 106 min (range: 63–151 min) and the mean extracor-
poreal circulation (ECC) time was 139 min (range: 94–202 min).
Intraoperative characteristics of patents with prosthetic valve
endocarditis (PVE) are listed in Table 1.
Data collection
All patients were reached remotely through phone interview, mail
questionnaire, referral cardiologists or family doctors. Clinical and
echocardiographic examinations were obtained at our institution or
by external cardiologists, according to a common evaluation protocol.
One patient was lost to follow-up (last follow-up time: June 2010).
Two patients underwent a cardiac reoperation. In both cases,
redo surgery was not related to aortic prosthetic malfunction or
degeneration, but to a supervening mitral valve or coronary artery
pathology.
Statistical methods
Statistical analysis was performed according to the type of para-
meters. For quantitative variables, summary statistics are reported
using mean, standard deviation, median, quartiles and extreme
values. For qualitative variables, number of patients and occur-
rence (percentage) are reported. Percentages are calculated on
the non-missing data.
Cumulative freedom from events was evaluated using the
method of Kaplan–Meier for the death and reoperation.
The degree of uncertainty in each actuarial analysis is expressed
with 95% confidence limits. The 95% confidence interval bounds for
the cumulative freedom were calculated according to the method
proposed by Greenwood. Statistical analyses were performed using
SAS software (Release 9.2, by SAS Institute Inc., Cary, NC, USA).
RESULTS
Early mortality and patient status at discharge
Early 30-day hospital mortality was 0 (0%). The mean length of
stay in intensive care unit was 62.3 h (range: 18–501 h), with a
mean duration of mechanical ventilation of 20 ± 20 h (range:
1–312 h). All the patients discharged from our unit were admitted
to the department of infectious disease for close observation and
completion of the antibiotic therapy. At hospital discharge, all the
patients were alive and in satisfactory clinical conditions. At the
echo examination, the mean ejection fraction (EF) was 54 ± 8%
(range: 35–65%).
The residual peak and mean transvalvular gradient were 17
mmHg (range: 11–30 mmHg) and 8 mmHg (range: 5–15 mmHg), re-
spectively. There was no residual aortic incompetence at discharge,
with complete exclusion of the abscess cavities, when present.
Late mortality
There were four late deaths (15.4%), all for non-cardiac causes. At
9 years, freedom from cardiac death was 100% and is reported in
Fig. 2.
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Reoperations and valve-related complications
There were two cardiac reoperations (8%). Freedom from
valve-related reoperation is reported in Fig. 3. In these two cases,
surgery was not related to the first operation for ABE and did not
involve the aortic valve. Freedom from recurrent infection is illu-
strated in Fig. 4.
Intermediate-time results
Follow-up time ranged between 3 months and 12 years (mean:
4.9 ± 3.3 years). One patient was lost to follow-up. The remain-
ing patients are in excellent clinical conditions. At the time of
the last follow-up control, 87% of the patients were in Class
NYHA I–II. At last echocardiographic examination, the mean EF
was 59 ± 5% (50–70%), the transaortic peak gradient was 17
mmHg (11–30 mmHg) and the mean gradient was 8 mmHg
(5–15 mmHg). Aortic valve insufficiency was absent in 83% of
cases and mild to moderate in 17% (mild in two cases, moderate
in one). In all instances, it was related to late dilatation of the
aortic root.
DISCUSSION
Two well-known key factors in the treatment of ABE involving the
aortic valve are the timing of surgery and the extent of resection
of the infected tissue, particularly when an abscess cavity is
present. Delay in surgical treatment has a great influence on mor-
tality and morbidity; incomplete eradication of bacterial debris is
responsible for recurrent infections. Furthermore, the type of bac-
terial agent should drive the therapeutic decision towards an
earlier and aggressive medical and surgical therapy, before aortic
root abscess develops.
As far as the best surgical approach, the choice of the aortic
prosthesis (mechanical, biological stented and stentless, and
homografts) and the complete exclusion of the abscess cavities
are two crucial points. In younger patients, with aortic root
abscesses, the Ross operation can be an option [2, 3].
The aortic homograft is considered by many authors as the gold
standard for the treatment of aortic ABE [1, 4–6]. Yankah et al. [7]
reported 91% freedom from reinfection and 70% survival at 17
years in a series of 161 patients with PVE treated with homograft.
Sabik et al. [8] reported a freedom from reinfection at 17 years of
95% in a cohort of 103 consecutive patients. Grinda et al. [9]
reported a freedom from reinfection at 10 years of 93% in a series
of 104 patients. The reinfection rate in all the reported series of
PVE treated with homograft is low, ranging between 3.8 and 6.8%.
Similar results, however, have been reported by many authors
with the use of stentless Dacron-free aortic prostheses. In particu-
lar, Siniawski et al. [10] compared two groups of patients treated
with stentless prosthesis and aortic homograft, without finding any
difference in terms of reinfection rate (4% in both) and mortality
(12 vs 16%, in the stentless prosthesis vs aortic homograft group,
respectively).
In 2008 and 2010, Musci et al. [11, 12] studied two large series
of 255 and 221 patients with PVE with a reinfection rate of 8.6 and
5.4%, respectively. In the second study, the freedom from reopera-
tion and reinfection was 92% at 10 years.
Less satisfactory results are reported when a stentless Dacron-
covered aortic valve is used. In a series of 32 patients with PVE
receiving a Freestyle implant, Heinz et al. [13] reported a 10-year
actuarial survival and freedom from reoperation for prosthetic
dysfunction and recurrent infection of 54.2% and of 53.1%,
respectively.Figure 2: Freedom from cardiac death.
Figure 3: Freedom from reoperation (A) and valve-related reoperation (B).
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The SPF is a Dacron-free stentless valve made of two layers of
bovine pericardium, stabilized in glutaraldehyde, detoxified and
stored in an aldehyde-free solution. Since 2003, 320 patients
underwent aortic valve replacement with SPF in our institution, of
these 26 patients presented with aortic ABE. In 17 cases, the infec-
tion involved the native aortic valve, and the prosthesis in the
remaining ones. An abscess cavity of the aortic root was found in
16 cases. Three patients (11%) required an emergent surgery.
Concomitant procedures were carried out in 7 patients (27%).
SPF valve is a user-friendly valve. A possible drawback of SPF
could be related to the implantation technique, similar to homo-
graft that requires a greater surgical expertise and the slightly
longer cross-clamp time. The pericardial tissue of the inflow skirt
and of the prosthetic sinuses can be trimmed and adapted to the
anatomy of the patient. This prosthesis is suitable to the treatment
and replacement of prosthetic aortic valves with endocarditis,
with or without destructive abscesses of the aortic root, and it is
particularly indicated when these abscesses extend to the aortic-
mitral fibrous continuity. It is possible in the majority of the
cases to completely exclude the infected tissues, after accurate
curettage, local disinfection and complete reconstruction of the
ventricular-aortic junction.
In our opinion, besides the remarkable resistance to infections,
the main benefit from the use of the SPF stentless valve is the lack of
need for any patch material or interrupted, pledgeted stitches,
which are necessary to exclude abscesses. This way larger size pros-
thetic implants and a more linear aortic flow are achieved along
with shorter cross-clamping time. This is particularly important since
the use of undersized prostheses was identified as an incremental
risk factor for reoperation [14]. No patient–prosthesis mismatch was
observed in our series and actually 70% of patients received an
implant larger than 23 mm, and 50% larger than 25 mm [mean
implant size: 25.6 ± 2.3 mm (range: 21–29 mm)]. The residual aortic
mean and peak gradients at discharge and at follow-up were close
to physiological findings, and the average length of aortic cross-
clamp was comparable with the one from routine procedure of
aortic valve replacement. No patient in this series required pace-
maker implantation.
Sponga et al. [15] have recently reported a similar experience of
aortic root reconstruction with the SPF valve. A series of 40 patients
affected by PVE were operated between 2007 and 2015, using SPF
stentless valve to reconstruct the aortic root. They reported a 10%
early mortality and a survival rate of 85% at 1 year, and 76% at
5 years, with 100% freedom from reoperation and reinfection at 5
years. The haemodynamic outcome was satisfactory, with very low
residual aortic gradients, and normalized EF.
In conclusion, the stentless aortic Dacron-free prostheses can be
considered a valid alternative to aortic homografts in cases of ABE
of the aortic valve, also considering that aortic homografts are not
available in most cardiac centres. Our experience has demonstrated
along with other authors [15] that SPF represents a valid solution for
aortic valve replacement in cases of ABE of the aortic valve, particu-
larly when complicated by aortic root or annular abscesses. One of
the main advantages of this versatile and user-friendly prosthesis is
the possibility of tailoring the valve to the anatomy of the patient’s
aortic root, with the possibility of excluding all abscesses and
infected tissue using the inferior valve skirt. Furthermore, the excel-
lent haemodynamic behaviour is maintained over the time along
with an adequate resistance to infections. However, a longer follow-
up time is required to drop reliable information about the durability
and the freedom from recurrent endocarditis and thromboembolic
events of SPF aortic prosthesis.
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APPENDIX. CONFERENCE DISCUSSION
Dr Sádaba (Pamplona, Spain): Congratulations because your results in a very
complex group of patients have been excellent. We have been seeing mortal-
ities around 10% and you have zero mortality, so just very good results.
I have two questions. Firstly have you referred to it already and is it the 15%
prevalence of at least mild aortic regurgitation. Now, we would see this in trans-
catheter aortic valve implantation patients and we say that’s not good enough.
Would you have any particular concerns about this?
Dr Stefanelli: As I said, in all of the cases, the residual incompetence was due to
aortic root dilatation. Maybe, in those patients we would have had to replace the
ascending aorta just to avoid the problem in the future. Even though this valve has
a very high coaptation area, with the progressive dilatation of the sinotubular
junction this could be insufficient to guarantee the competence of the valve.
Dr Sádaba: Just following on this, I mean I understand that the Freedom is a
supra-annular prosthesis normally. But in these cases you implanted it in a sub-
annular position, isn’t it?
Dr Stefanelli: Yes.
Dr Sádaba: Do you think that that could have an impact, be responsible for
aortic regurgitations, or not?
Dr Stefanelli: Well, actually it’s not really supra-annular. In the majority of
cases I didn’t use the entire inferior skirt, but I was able to tailor the prosthesis
according to the amount of pericardium which I needed to exclude the
abscess. This is a prosthesis that I’ve implanted in more than 330 cases. In the
normal cases, I try to cut away all the inferior skirt in order to lower the implant
of the prosthesis.
Dr Sádaba: And just a second question. According to your Kaplan-Meier
curve, you only had 2 patients at risk at 10 years. So, as far as I understand,
there are only 2 patients who have had a follow-up of 10 years and then you
refer to 2 patients who required reoperation at 10 years. So is there any con-
cerns about the long-term durability of this prosthesis? Do you have any data
on other studies?
Dr Stefanelli: Well, in spite of the fact that this prosthesis has been on the
market for 25 years, there are only a few studies reporting long-term results.
The longer follow-up time, as reported by a paper from Mazzucco is 10 years,
and they reported a 96% freedom from re-operation due to structural valve de-
terioration. We are collecting the data of 330 patients who received a Freedom
aortic valve, and we have reached almost 14 years follow-up.
As far as these 2 cases reported with structural deterioration, one case was
the only case where I had to implant a 21 prosthesis, so maybe this could be
the reason of early failure. The second was a case where there was a fracture,
located at the commissure between the left coronary and the non-coronary
cusp, probably related to a technical error, as you know, in stentless valve,
when the implant is not symmetrical, abnormal shear stresses develop, influen-
cing the long-term results of these valves.
Dr M. Musci (Berlin, Germany): One comment, Dr Stefanelli. I think that with
your small amount of data, multivariate analysis is not allowed and you should
use another statistical tool. Because you only have 26 patients, in my opinion
only univariate analysis is allowed.
Dr Stefanelli: You’re right. I think you’re right.
Dr El Khoury: I missed your indications. All your endocarditis were acute or
healed endocarditis? Because your results are excellent really, better than
aortic valve replacement standard.
Dr Stefanelli: Maybe this could be related to the small number of patients,
almost two patients per year. In the total number of patients operated for acute
bacterial endocarditis, of course, the numbers are different. Besides, we are
very accurate when we do this operation.
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